Christoph Kern1,2, Dun Jack Fu1, Josef Huemer1,3, Livia Faes1, Siegfried K Wagner1, Karsten Kortuem1,2, Praveen J Patel1,4, Ranjan Rajendram1, Konstantinos Balaskas1,4, Robin Hamilton1, Dawn A Sim1,4,5, Pearse A Keane6,7,8. 1. Moorfields Eye Hospital, London, UK. 2. Department of Ophthalmology, University Hospital LMU, Munich, Germany. 3. Eye Department, Hanusch Hospital, Vienna, Austria. 4. National Institute for Health and Research (NIHR) Biomedical Centre, Moorfields Eye Hospital, London, UK. 5. Institute of Ophthalmology, University College of London (UCL), London, UK. 6. Moorfields Eye Hospital, London, UK. pearse.keane1@nhs.net. 7. National Institute for Health and Research (NIHR) Biomedical Centre, Moorfields Eye Hospital, London, UK. pearse.keane1@nhs.net. 8. Institute of Ophthalmology, University College of London (UCL), London, UK. pearse.keane1@nhs.net.
Abstract
OBJECTIVES: The objective of this paper is to evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO). METHODS: In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of VA outcomes was reported for all eyes over a 4-year observation period. RESULTS: Our cohort includes 2614 DMO eyes of 1964 patients over 48 months. Cox proportional-hazards modelling identified injection number (hazard ratio (HR) = 1.18), male gender (HR = 1.13) and baseline VA (HR = 1.09) as independent predictors to reach a favourable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 letters by 14.7 months. CONCLUSION: To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our data set available on an open-source data repository as a resource for clinical researchers globally.
OBJECTIVES: The objective of this paper is to evaluate visual acuity (VA) outcomes of intravitreal anti-vascular endothelial growth factor (VEGF) in diabetic macular oedema (DMO). METHODS: In this retrospective cohort study, electronic medical records for all patients undergoing intravitreal injections in a tertiary referral centre between March 2013 and October 2018 were analysed. Treatment response in terms of VA outcomes was reported for all eyes over a 4-year observation period. RESULTS: Our cohort includes 2614 DMO eyes of 1964 patients over 48 months. Cox proportional-hazards modelling identified injection number (hazard ratio (HR) = 1.18), male gender (HR = 1.13) and baseline VA (HR = 1.09) as independent predictors to reach a favourable visual outcome of more than 70 Early Treatment Diabetic Retinopathy Study letters. Half of our cohort reached 70 letters 1.9 months after starting anti-VEGF therapy. Of those that reached 70 letters, 50% fell below 70 letters by 14.7 months. CONCLUSION: To date, this is the largest single centre cohort study and over the longest observation period reporting on real-life outcomes of anti-VEGF in DMO. We have made an anonymised version of our data set available on an open-source data repository as a resource for clinical researchers globally.
Authors: Thomas Wecker; Christoph Ehlken; Anima Bühler; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Andreas Stahl Journal: Br J Ophthalmol Date: 2016-05-23 Impact factor: 4.638